KY
KYNB
KYNTRA BIO, INC.
$6.88
-1.01%
$28.1M
No data for this timeframe.
Vol
Market Cap$28.1M
Cap SizeNano Cap
Inst. Holders5 funds
Inst. Value$2.5M
Inst. Activity2 buys / 0 sells
Insider Activity2B / 0S
Insider Net $$39.7K
SEC Reports1
Press Releases1
Recent Activity
May 14, 2026
Insider
Wettig Thane bought 2,800 shares
CEO @ $7.09 ($19.9K)
May 14, 2026
Insider
Wettig Thane bought 2,800 shares
CEO @ $7.09 ($19.9K)
May 11, 2026
SEC
Kyntra Bio reported Q1 2026 revenue of $3.7M (above $1.6M consensus) but EPS of -$3.74 missed the -$3.35 consensus by 11
PRESS-RELEASE — Impact 5/10
May 11, 2026
earnings
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
<p>SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financ
Mar 16, 2026
Press
Kyntra Bio reported a significant year-over-year decline in revenue and wider net losses from continuing operations for
Impact 6/10
Mar 6, 2026
Insider
Wettig Thane sold 277 shares
CEO @ $6.84 ($1.9K)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
61,211 shares ($537.4K)
Inst.
MORGAN STANLEY — DOUBLED
5,924 shares ($52.0K)
Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$43.00 (Sep 2025)
Current $6.88
Low $43.00
Median $43.00
High $43.00
1 analysts
$43.00
$43.00
Analyst Ratings
2Strong Buy
4Buy
2Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Sep 24, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Aug 7, 2025 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-3.27 ▲ +2.4% | $-3.62 — $-2.92 | -74% YoY | 2 |
| Next Q | $-3.38 ▲ +0.6% | $-3.87 — $-2.90 | -107% YoY | 2 |
| Current FY | $-13.89 ▼ -2.6% | $-15.37 — $-12.41 | -131% YoY | 2 |
| Next FY | $-9.73 ▲ +5.1% | $-11.89 — $-7.57 | 30% YoY | 2 |
Latest Reports
MIXED
PRESS-RELEASE
5/10
Kyntra Bio reported Q1 2026 revenue of $3.7M (above $1.6M consensus) but EPS of -$3.74 missed the -$3.35 consensus by 11
May 11, 2026
BEARISH
Press
6/10
Kyntra Bio reported a significant year-over-year decline in revenue and wider net losses from continuing operations for
Mar 16, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.6M | NEW |
| TWO SIGMA INVESTMENTS, LP | $537.4K | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $278.2K | DOUBLED |
| MORGAN STANLEY | $52.0K | DOUBLED |
| BANK OF AMERICA CORP | $5.2K | ADD |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 14, 2026 | Wettig Thane | BUY | $19.9K |
| May 14, 2026 | Wettig Thane | BUY | $19.9K |
| Mar 6, 2026 | Wettig Thane | F | $1.9K |
| Mar 6, 2026 | DeLucia David | F | $410.40 |
| Feb 3, 2026 | Wettig Thane | A | $0.00 |
5 institutional holders with $2.5M total value (281,384 shares) as of 2025-Q4. Top holders: VANGUARD, TWO, RENAISSANCE. Net buying activity: 2 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 181,973 | $1.6M | 64.7% | NEW |
| 2 | TWO SIGMA INVESTMENTS, LP | 61,211 | $537.4K | 21.8% | ADD +52.2% |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 31,681 | $278.2K | 11.3% | DOUBLED +161.9% |
| 4 | MORGAN STANLEY | 5,924 | $52.0K | 2.1% | DOUBLED +283.2% |
| 5 | BANK OF AMERICA CORP /DE/ | 595 | $5.2K | 0.2% | ADD +34.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| TWO SIGMA INVESTMENTS, LP | ADD | 40,218 | 61,211 | +52.2% | $537.4K | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 1,546 | 5,924 | +283.2% | $52.0K | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | DOUBLED | 14,111 | 40,218 | +185.0% | $492.7K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 11,181 | 29,281 | +161.9% | $358.7K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | ADD | 443 | 595 | +34.3% | $7.3K | 2025-Q3 |
| VANGUARD GROUP INC | NEW | — | 178,040 | — | $943.6K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 14,111 | — | $74.8K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 11,181 | — | $59.3K | 2025-Q2 |
| UBS Group AG | NEW | — | 10,287 | — | $54.5K | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | EXIT | 481,265 | 0 | -100.0% | $0.00 | 2025-Q2 |
| VANGUARD GROUP INC | EXIT | 5,859,125 | 0 | -100.0% | $0.00 | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 584,451 | 0 | -100.0% | $0.00 | 2025-Q2 |
| MORGAN STANLEY | EXIT | 97,744 | 0 | -100.0% | $0.00 | 2025-Q2 |
| UBS Group AG | EXIT | 245,555 | 0 | -100.0% | $0.00 | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 1,358,712 | 481,265 | -64.6% | $149.1K | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 168,800 | 219,500 | +30.0% | $68.0K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 37,958 | 97,744 | +157.5% | $30.3K | 2025-Q1 |
| FMR LLC | NEAR_EXIT | 414,580 | 10,430 | -97.5% | $3.2K | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 753,140 | 1,358,712 | +80.4% | $719.4K | 2024-Q4 |
| UBS Group AG | DOUBLED | 24,663 | 196,635 | +697.3% | $104.0K | 2024-Q4 |
| CITADEL ADVISORS LLC | TRIM | 349,157 | 168,800 | -51.7% | $89.4K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | 58,027 | 0 | -100.0% | $0.00 | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 58,027 | — | $23.2K | 2024-Q3 |
| MORGAN STANLEY | NEAR_EXIT | 236,476 | 41,718 | -82.4% | $16.7K | 2024-Q3 |
2 unique insiders with 2 transactions. Net insider value: $39.7K ($39.7K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 14, 2026 | Wettig Thane | CEO | BUY | 2,800 | $7.09 | $19.9K |
| May 14, 2026 | Wettig Thane | CEO | BUY | 2,800 | $7.09 | $19.9K |
| Mar 6, 2026 | Wettig Thane | CEO | F | 277 | $6.84 | $1.9K |
| Mar 6, 2026 | DeLucia David | Chief Financial Officer | F | 60 | $6.84 | $410.40 |
| Feb 3, 2026 | Wettig Thane | CEO | A | 60,000 | $0.00 | $0.00 |
| Feb 3, 2026 | DeLucia David | Chief Financial Officer | A | 26,000 | $0.00 | $0.00 |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 5.0/10.
Historical analyst distribution (last covering-analyst action Sep 2025): 75% buy across 8 analysts — 2 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Sep 2025. No current recommendation available.
$43.00 mean target (Sep 2025)
$43.00 Low
$43.00 High
| Metric | Value |
|---|---|
| Current Price | $6.88 |
| Target Low | $43.00 |
| Target Mean | $43.00 |
| Target Median | $43.00 |
| Target High | $43.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-3.27 | $-3.62 | $-2.92 | -73.9% | +2.4% | 0↑ 1↓ | $0.0B | -9.5% | 2 |
| Next Q 2026-09-30 |
$-3.38 | $-3.87 | $-2.90 | -106.8% | +0.6% | 0↑ 1↓ | $0.0B | 16.2% | 2 |
| Current FY 2026-12-31 |
$-13.89 | $-15.37 | $-12.41 | -130.6% | -2.6% | 0↑ 1↓ | $0.0B | 23.4% | 2 |
| Next FY 2027-12-31 |
$-9.73 | $-11.89 | $-7.57 | 30.0% | +5.1% | 0↑ 1↓ | $0.0B | -15.7% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-3.270 | |
| 7d ago | $-3.350 | +0.080 |
| 30d ago | $-3.350 | +0.080 |
| 60d ago | $-4.250 | +0.980 |
| 90d ago | $-4.250 | +0.980 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Sep 24, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 7, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Apr 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Mar 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Feb 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% | |
| Jan 1, 2026 | 2 | 4 | 2 | 0 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 11, 2026
earnings
Kyntra Bio Reports First Quarter 2026 Financial Results and Provides Business Update
<p>SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the first quarter 2026 and provide
May 11, 2026
earnings_calendar
KYNB Q1 2026 Earnings After Market Close — 2026-05-11
May 4, 2026
earnings
Kyntra Bio to Report First Quarter 2026 Financial Results
<p align="left">SAN FRANCISCO, May 04, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio, Inc. (Nasdaq: KYNB) will announce first quarter 2026 financial results o
Apr 8, 2026
other
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
<p align="justify">SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the
Mar 16, 2026
earnings
Kyntra Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p>SAN FRANCISCO, March 16, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today reported financial results for the fourth quarter and full year
Mar 16, 2026
earnings_calendar
KYNB Q4 2025 Earnings After Market Close — 2026-03-16
Mar 9, 2026
earnings
Kyntra Bio to Report Fourth Quarter and Full Year 2025 Financial Results
<p>SAN FRANCISCO, March 09, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB), formerly FibroGen (Nasdaq: FGEN), will announce fourth quarter and f
Mar 2, 2026
earnings_calendar
KYNB Q4 2025 Earnings After Market Close — 2026-03-02